• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乙醛脱氢酶 1 表达与口腔扁平苔藓恶性潜能相关。

Aldehyde dehydrogenase 1 expression correlated with malignant potential of oral lichen planus.

机构信息

Department of Stomatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

出版信息

Ann Diagn Pathol. 2013 Oct;17(5):408-11. doi: 10.1016/j.anndiagpath.2013.04.008. Epub 2013 May 23.

DOI:10.1016/j.anndiagpath.2013.04.008
PMID:23707659
Abstract

Oral lichen planus (OLP) is a potentially malignant disorder associated with an increased risk of oral squamous cell carcinoma (OSCC). The objective of this study was to determine protein expression of cancer stem cell marker aldehyde dehydrogenase 1 (ALDH1) in a series of patients with OLP and evaluate the correlation between ALDH1 expression and the risk of progression to OSCC. In a retrospective study, ALDH1 expression was determined using immunohistochemistry in samples from 101 patients with OLP who received a mean follow-up of 5 years, including 89 patients with untransformed OLP that did not develop into OSCC and 12 patients with malignant transformed OLP that had developed into OSCC. Analysis of 10 cases of normal oral mucosa and 6 cases of postmalignant OSCC form previously diagnosed OLP was also performed. The results showed that ALDH1 expression was observed in 27 (30.3%) of 89 cases of untransformed OLP and in 8 (66.7%) of 12 cases of transformed OLP (P = .021). Aldehyde dehydrogenase 1 was not expressed in normal oral mucosa, but it overexpressed in the 6 cases (100%) of OSCC. Multivariate analysis revealed that ALDH1 expression was significantly associated with a 6.71-fold (95% confidence interval, 1.64-27.42; P = .008) increased risk of malignant transformation. Collectively, ALDH1 expression was significantly associated with malignant transformation in a large series of patients with OLP. Our findings suggested that ALDH1 expression may identify a subgroup of a higher risk of malignant transformation of OLP.

摘要

口腔扁平苔藓(OLP)是一种潜在的恶性疾病,与口腔鳞状细胞癌(OSCC)的风险增加有关。本研究的目的是确定一系列 OLP 患者中癌症干细胞标志物醛脱氢酶 1(ALDH1)的蛋白表达,并评估 ALDH1 表达与向 OSCC 进展的风险之间的相关性。在一项回顾性研究中,使用免疫组织化学法检测了 101 例 OLP 患者的样本中 ALDH1 的表达,这些患者的平均随访时间为 5 年,其中 89 例未发生 OSCC 的未恶变 OLP 患者和 12 例发生恶变的 OLP 患者发生了 OSCC。还分析了 10 例正常口腔黏膜和 6 例先前诊断为 OLP 的恶性 OSCC 病例。结果显示,在 89 例未恶变的 OLP 中,有 27 例(30.3%)和 12 例恶变的 OLP 中,有 8 例(66.7%)观察到 ALDH1 表达(P =.021)。正常口腔黏膜不表达 ALDH1,但在 6 例(100%)OSCC 中过度表达。多变量分析显示,ALDH1 表达与恶变风险增加 6.71 倍(95%置信区间,1.64-27.42;P =.008)显著相关。总的来说,在一大系列 OLP 患者中,ALDH1 表达与恶性转化显著相关。我们的研究结果表明,ALDH1 表达可能鉴定出 OLP 恶性转化风险较高的亚组。

相似文献

1
Aldehyde dehydrogenase 1 expression correlated with malignant potential of oral lichen planus.乙醛脱氢酶 1 表达与口腔扁平苔藓恶性潜能相关。
Ann Diagn Pathol. 2013 Oct;17(5):408-11. doi: 10.1016/j.anndiagpath.2013.04.008. Epub 2013 May 23.
2
Bmi1 expression in oral lichen planus and the risk of progression to oral squamous cell carcinoma.BMI1 在口腔扁平苔藓中的表达与口腔鳞状细胞癌进展的风险。
Ann Diagn Pathol. 2013 Aug;17(4):327-30. doi: 10.1016/j.anndiagpath.2013.03.002. Epub 2013 Apr 29.
3
CD133 expression in oral lichen planus correlated with the risk for progression to oral squamous cell carcinoma.口腔扁平苔藓中CD133的表达与进展为口腔鳞状细胞癌的风险相关。
Ann Diagn Pathol. 2013 Dec;17(6):486-9. doi: 10.1016/j.anndiagpath.2013.06.004. Epub 2013 Aug 2.
4
Evaluation of MYC status in oral lichen planus in patients with progression to oral squamous cell carcinoma.评估 MYC 状态在口腔扁平苔藓患者进展为口腔鳞状细胞癌中的作用。
Br J Dermatol. 2013 Jul;169(1):106-14. doi: 10.1111/bjd.12303.
5
Squamous cell carcinoma development in previously diagnosed oral lichen planus: de novo or transformation?先前诊断的口腔扁平苔藓中鳞状细胞癌的发生:新发还是转化?
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Nov;112(5):592-6. doi: 10.1016/j.tripleo.2011.05.029. Epub 2011 Aug 24.
6
Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus.Podoplanin 和 ABCG2:口腔扁平苔藓恶性转化风险标志物。
Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):844-9. doi: 10.1158/1055-9965.EPI-09-0699. Epub 2010 Mar 3.
7
The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective five-year follow-up study of 192 patients.口腔扁平苔藓和口腔苔藓样病变的潜在癌前特征:192例患者的前瞻性五年随访研究
Oral Oncol. 2007 Sep;43(8):742-8. doi: 10.1016/j.oraloncology.2006.09.006. Epub 2006 Nov 16.
8
Oral lichen planus and malignant transformation: a longitudinal cohort study.口腔扁平苔藓与恶性转化:一项纵向队列研究。
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Sep;112(3):328-34. doi: 10.1016/j.tripleo.2011.04.009. Epub 2011 Jul 22.
9
Malignant transformation of oral lichen planus.口腔扁平苔藓的恶性转化
Eur J Surg Oncol. 1999 Oct;25(5):520-3. doi: 10.1053/ejso.1999.0689.
10
Caveolin-1 expression in oral lichen planus, dysplastic lesions and squamous cell carcinoma.小窝蛋白-1在口腔扁平苔藓、发育异常病变及鳞状细胞癌中的表达
Pathol Res Pract. 2017 Jul;213(7):809-814. doi: 10.1016/j.prp.2017.03.006. Epub 2017 Mar 9.

引用本文的文献

1
A Molecular Hypothesis on Malignant Transformation of Oral Lichen Planus: A Systematic Review and Meta-Analysis of Cancer Hallmarks Expression in This Oral Potentially Malignant Disorder.口腔扁平苔藓恶性转化的分子假说:对这种口腔潜在恶性疾病中癌症特征表达的系统评价和荟萃分析
Cancers (Basel). 2024 Jul 23;16(15):2614. doi: 10.3390/cancers16152614.
2
Investigating the factors proposed in oral lichen planus malignant transformation: A literature review.口腔扁平苔藓恶变相关因素的研究:文献综述
Health Sci Rep. 2023 May 17;6(5):e1267. doi: 10.1002/hsr2.1267. eCollection 2023 May.
3
Literature review of cancer stem cells in oral lichen planus: a premalignant lesion.
口腔扁平苔藓中癌干细胞的文献综述:一种癌前病变
Stem Cell Investig. 2021 Dec 30;8:25. doi: 10.21037/sci-2020-049. eCollection 2021.
4
Increased salivary aldehyde dehydrogenase 1 in non-reticular oral lichen planus.非网状口腔扁平苔藓中唾液醛脱氢酶1增加。
An Bras Dermatol. 2017 Mar-Apr;92(2):168-171. doi: 10.1590/abd1806-4841.20174964.